These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

374 related articles for article (PubMed ID: 6376026)

  • 1. Acute and chronic effects of sulfonylurea drugs on pancreatic islet function in man.
    Pfeifer MA; Halter JB; Judzewitsch RG; Beard JC; Best JD; Ward WK; Porte D
    Diabetes Care; 1984; 7 Suppl 1():25-34. PubMed ID: 6376026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin secretion in diabetes mellitus.
    Pfeifer MA; Halter JB; Porte D
    Am J Med; 1981 Mar; 70(3):579-88. PubMed ID: 7011013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms for hyperglycemia in type II diabetes mellitus: therapeutic implications for sulfonylurea treatment--an update.
    Porte D; Kahn SE
    Am J Med; 1991 Jun; 90(6A):8S-14S. PubMed ID: 1872310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucose regulation in non-insulin-dependent diabetes mellitus. Interaction between pancreatic islets and the liver.
    Halter JB; Ward WK; Porte D; Best JD; Pfeifer MA
    Am J Med; 1985 Aug; 79(2B):6-12. PubMed ID: 2863979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective unresponsiveness of pancreatic beta-cells to acute sulfonylurea stimulation during sulfonylurea therapy in NIDDM.
    Karam JH; Sanz N; Salamon E; Nolte MS
    Diabetes; 1986 Dec; 35(12):1314-20. PubMed ID: 3533680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE; Matthews DR
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic chlorpropamide therapy of noninsulin-dependent diabetes augments basal and stimulated insulin secretion by increasing islet sensitivity to glucose.
    Judzewitsch RG; Pfeifer MA; Best JD; Beard JC; Halter JB; Porte D
    J Clin Endocrinol Metab; 1982 Aug; 55(2):321-8. PubMed ID: 7045153
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM.
    Rachman J; Payne MJ; Levy JC; Barrow BA; Holman RR; Turner RC
    Diabetes Care; 1998 May; 21(5):810-6. PubMed ID: 9589246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutical concentrations of tolbutamide, glibenclamide, gliclazide and gliquidone at different glucose levels: in vitro effects on pancreatic A- and B-cell function.
    Gregorio F; Ambrosi F; Cristallini S; Pedetti M; Filipponi P; Santeusanio F
    Diabetes Res Clin Pract; 1992 Dec; 18(3):197-206. PubMed ID: 1289021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of gliquidone action by forskolin in the pancreas of normal and GK rats.
    Leclercq-Meyer V; Malaisse WJ
    Am J Physiol; 1997 Jul; 273(1 Pt 1):E52-8. PubMed ID: 9252479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metabolic, cationic and secretory effects of hypoglycemic sulfonylureas in pancreatic islets.
    Kawazu S; Sener A; Couturier E; Malaisse WJ
    Naunyn Schmiedebergs Arch Pharmacol; 1980 Jul; 312(3):277-83. PubMed ID: 6995864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic sensitivity to insulin: effects of sulfonylurea drugs.
    Del Prato S; Vigili de Kreutzenberg S; Riccio A; Tiengo A
    Am J Med; 1991 Jun; 90(6A):29S-36S. PubMed ID: 1872301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyaluronidase-induced inhibition of the insulinotropic action of sulfonylureas, leucine, and glucagon in rodent isolated pancreatic islets.
    Macchi IA; Zeytinoğlu FN
    Horm Metab Res; 1976 Mar; 8(2):92-6. PubMed ID: 177348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged sulfonylurea administration decreases insulin resistance and increases insulin secretion in non-insulin-dependent diabetes mellitus: evidence for improved insulin action at a postreceptor site in hepatic as well as extrahepatic tissues.
    Mandarino LJ; Gerich JE
    Diabetes Care; 1984; 7 Suppl 1():89-99. PubMed ID: 6376034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current concepts of the pancreatic and extrapancreatic mechanisms of the action of peroral hypoglycemic sulfonylurea preparations].
    Poltorak VV; Gladkikh AI
    Probl Endokrinol (Mosk); 1985; 31(2):76-85. PubMed ID: 2859589
    [No Abstract]   [Full Text] [Related]  

  • 16. Glucose modulation of insulin and glucagon secretion in nondiabetic and diabetic man.
    Hollander PM; Asplin CM; Palmer JP
    Diabetes; 1982 Jun; 31(6 Pt 1):489-95. PubMed ID: 6759265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pathophysiology of diabetes mellitus type 2 and the mechanism of action and indications for using hypoglycemic sulfonylurea derivatives].
    Tatoń J; Koliński P
    Pol Tyg Lek; 1985 May; 40(18):505-11. PubMed ID: 3892513
    [No Abstract]   [Full Text] [Related]  

  • 18. Glucose modulates the amount, but not the kinetics, of insulin released by sulfonylureas.
    Gregorio F; Ambrosi F; Filipponi P; Cristallini S; Santeusanio F
    J Diabetes Complications; 1994; 8(4):204-12. PubMed ID: 7833495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular loci of sulfonylurea actions.
    Lebovitz HE
    Diabetes Care; 1984; 7 Suppl 1():67-71. PubMed ID: 6376031
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Islet dysfunction in non-insulin-dependent diabetes mellitus.
    Kahn SE; Porte D
    Am J Med; 1988 Nov; 85(5A):4-8. PubMed ID: 3057894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.